Is tirzepatide legal in the United States? Yes, as a prescription medicine. FDA has approved it twice, as Mounjaro and Zepbound. The harder questions are about compounding after the shortage ended, and about tirzepatide sold outside the prescription system. This guide takes them one at a time, using Drugs@FDA, DailyMed, FDA orders and warning letters checked on November 17, 2026.
Quick answer: Tirzepatide is legal to prescribe and dispense as Mounjaro or Zepbound. Compounding is now limited. A 503A pharmacy may not regularly compound copies of the approved products, and a 503B outsourcing facility does not meet the 503B conditions when it compounds tirzepatide from bulk. FDA treats tirzepatide sold for human use outside an approved application as an unapproved new drug, and a “research use only” label has not changed that when marketing showed human use. Research-grade tirzepatide is a laboratory reagent, not an alternative to a prescription medicine.
This article summarizes public regulatory records. It is not legal advice. For a decision about your own situation, ask a lawyer.
Is tirzepatide FDA-approved?
Yes. Drugs@FDA lists two applications from Eli Lilly, both with marketing status “Prescription”:
- Mounjaro, NDA 215866, approved May 13, 2022 as a new molecular entity (Drugs@FDA); and
- Zepbound, NDA 217806, approved November 8, 2023 (Drugs@FDA).
The current Mounjaro label, revised in August 2026, lists two uses: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk of them (DailyMed). The current Zepbound label, also revised in August 2026, lists use with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction in adults with obesity, or adults with overweight and at least one weight-related comorbid condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity (DailyMed). For what the approved labels contain, see our page on semaglutide and tirzepatide prescription labels. For costs, see tirzepatide price.
Can tirzepatide still be compounded?
Only within narrow limits. Tirzepatide injection products were added to FDA’s shortage list on December 15, 2022. In a declaratory order dated December 19, 2024, FDA determined “that the tirzepatide injection product shortage is resolved” (FDA, 2024). FDA then gave compounders a wind-down period. After a court denied a preliminary injunction on March 5, 2025, FDA said the 503A period had ended; the 503B period ran to March 19, 2025 (FDA, 2026). On August 27, 2026, the Fifth Circuit affirmed judgment for FDA in the compounders’ challenge (No. 25-10600).
FDA’s current policy, updated April 1, 2026, sets out what remains:
- 503A pharmacies must compound for an individual patient on a prescription and may not compound essentially copies of a commercially available product “regularly or in inordinate amounts.” FDA does not intend to act against a pharmacy that fills four or fewer prescriptions of such a copy in a calendar month.
- 503B outsourcing facilities may compound from a bulk substance only if it is on the 503B bulks list or the drug is on the shortage list. FDA wrote: “Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list.”
On April 30, 2026, FDA proposed not to include tirzepatide on the 503B bulks list, finding “no clinical need” (FDA, 2026). Comments closed on July 30, 2026, and we found no final decision. In an April 7, 2026 warning letter, FDA told a registered outsourcing facility that its tirzepatide products were not eligible for the 503B exemptions because “tirzepatide does not appear on the 503B bulks list” (FDA, 2026). Compounded drugs are not FDA-approved. Our pages on compounded tirzepatide and 503A vs 503B compounding cover the details.
Has FDA warned sellers of unapproved tirzepatide?
Yes. FDA says it has warned companies that sold unapproved semaglutide, tirzepatide and similar products “falsely labeled” for research purposes or not for human consumption (FDA, 2026). Table 1 shows the letters and status checks we read.
Tirzepatide: approvals, FDA actions and status checks
| Date | What happened |
|---|---|
| May 13, 2022 | FDA approves Mounjaro (NDA 215866) |
| November 8, 2023 | FDA approves Zepbound (NDA 217806) |
| September 12, 2024 | Warning letter to an online seller of tirzepatide and semaglutide sold without a prescription |
| December 10, 2024 | Warning letter to a seller of tirzepatide labeled “research use only” |
| December 19, 2024 | FDA order: tirzepatide injection shortage resolved |
| February 26, 2025 | Warning letter over tirzepatide labeled “research use only” and “not for human consumption” |
| March 19, 2025 | Last day of FDA’s 503B wind-down period |
| February 20, 2026 | Warning letter over compounded tirzepatide marketed as having the same active ingredient as Mounjaro and Zepbound |
| March 31, 2026 | Warning letter to a seller of research-labeled tirzepatide and retatrutide |
| April 30, 2026 | FDA proposes not to include tirzepatide on the 503B bulks list |
| August 24, 2026 | Warning letters to two sellers of research-labeled tirzepatide |
| November 12, 2026 | DEA controlled substances list edition; tirzepatide not listed |
The research-labeled cases follow one pattern. The February 2025 letter named a product listed as “Tirzepatide (Mounjaro)” and quoted “research use only” and “not for human consumption.” The March 2026 letter quoted “Research Use Only.” The August 2026 letter to Tex Peptides quoted “not for human or veterinary use.” Each time, FDA wrote that evidence from the seller’s website established that the products were intended to be drugs for human use, and cited sections 505(a) and 301(d) of the Act. Our guide to FDA warning letters to peptide sellers lists each letter.
Is tirzepatide a controlled substance?
Not under federal law. Tirzepatide does not appear on the DEA’s alphabetical list of controlled substances, edition dated November 12, 2026 (DEA). That does not make a product lawful to sell as a drug. That question belongs to FDA.
What does research-use-only sale mean, and what are its limits?
A “research use only” label states the seller’s intended use: laboratory research, not use in people or animals. Research-grade tirzepatide is a laboratory reagent. It is not Mounjaro or Zepbound, it is not made under an approved application, and it is not a substitute for a prescription medicine.
The label does not decide the legal question by itself. FDA judges intended use by “objective intent,” which may be shown by a seller’s expressions or “the circumstances surrounding the distribution of the article” (21 CFR 201.128). When the evidence shows a product is meant for people, FDA can treat it as an unapproved new drug despite the label, as the letters above show.
Research-grade tirzepatide in our catalog is sold for laboratory research use only, not for human or veterinary use. See also what research use only means.
Frequently asked questions about tirzepatide legality
Is tirzepatide FDA-approved?
Yes, as Mounjaro (2022) and Zepbound (2023). Both are prescription-only.
Can a pharmacy still compound tirzepatide?
Only within limits. A 503A pharmacy may not regularly compound copies of the approved products. Tirzepatide is on neither the 503B bulks list nor FDA’s shortage list.
Does a “research use only” label make tirzepatide legal to sell?
Not by itself. FDA decides intended use from all the evidence. When that evidence showed human use, FDA treated research-labeled tirzepatide as an unapproved new drug.
Is tirzepatide a controlled substance?
No. It is not on the DEA’s federal list.
Is research-grade tirzepatide the same as Mounjaro or Zepbound?
No. The approved products are made and labeled under an FDA-approved application. Research-grade material is for laboratory research use only and is not an alternative to them.
What to know now
- FDA approval: Mounjaro (2022) and Zepbound (2023), prescription only.
- Shortage: resolved December 19, 2024; wind-down periods ended in March 2025.
- 503B: not on the bulks list or the shortage list; FDA proposed leaving it off the list.
- Enforcement: warning letters from 2024 to August 2026 looked past research-use labels.
- Controlled substance: not on the DEA’s federal list.
- Research grade: for laboratory research use only, not for human or veterinary use.
What we’re watching
FDA’s final decision on its proposal to leave tirzepatide off the 503B bulks list. New FDA warning letters to sellers of research-labeled tirzepatide. And further label changes for Mounjaro and Zepbound listed on Drugs@FDA.